Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

In early clinical results, Sarepta’s αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1 Company to host investor call on March 25, 2026, at 8:30 a.m. Eastern time CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar.